Divalproex Sodium in Nursing Home Residents With Possible or Probable Alzheimer Disease Complicated by Agitation
ABSTRACT Three placebo-controlled clinical trials have suggested the benefit of valproate for treatment of agitation associated with dementia; one was used as the basis for this multicenter trial, conducted by the Alzheimer's Disease (AD) Cooperative Study. It addresses the efficacy, safety, and tolerability of divalproex sodium for the treatment of agitation associated with dementia.
This was a randomized, double-blind, placebo-controlled clinical trial in 153 nursing home residents with probable or possible AD complicated by agitation; 110 (72%) completed the trial. Participants were randomized to treatment with divalproex sodium at a target dose of 750 mg/day (N = 75) or placebo (N = 78) for 6 weeks. The primary outcome measure was change from baseline on the Brief Psychiatric Rating Scale (BPRS) Agitation factor. Secondary outcomes included total BPRS, Clinical Global Impression of Change, Cohen-Mansfield Agitation Inventory score, and measures of safety and tolerability.
Compliance averaged 88%. Participants receiving divalproex achieved a mean dose of 800 mg/day. Change in mean BPRS Agitation factor scores did not differ between patients treated with divalproex and placebo, nor did secondary behavioral measures. Measures of safety and tolerability did not reveal clinically important drug/placebo differences.
This multicenter trial showed no benefit of divalproex sodium for treatment for agitation in dementia at a mean dose of 800 mg/day over 6 weeks. The results do not support findings from previous trials indicating possible benefit.
- SourceAvailable from: Dabao Zhang
[Show abstract] [Hide abstract]
- "One such treatment is the short-chain branched fatty acid, valproic acid (2- propylpentanoic acid, valproate; VPA), which is often administered to patients as the divalproex sodium formulation. Some studies suggest that VPA may afford symptomatic relief of agitation in people with dementia (Porsteinsson et al., 1997; Porsteinsson et al., 2003; Sival et al., 2002; Tariot et al., 2002), although the most recent study found no benefit (Tariot et al., 2005). A multicenter clinical trial is currently being conducted by the Alzheimer's Disease Cooperative Study (ADCS) that is investigating the potential for VPA to attenuate progression of the clinical features of AD (Tariot et al., 2002). "
ABSTRACT: The molecular profiling of peripheral tissues, including circulating leukocytes, may hold promise in the discovery of biomarkers for diagnosing and treating neurodegenerative diseases, including Alzheimer's disease (AD). As a proof-of-concept, we performed a proteomics study on peripheral leukocytes from patients with AD both before and during treatment with divalproex sodium. Using two-dimensional gel electrophoresis and MALDI-TOF mass spectrometry, we identified 10 differentially expressed proteins: two up-regulated proteins, 14-3-3 protein epsilon and peroxiredoxin 2; and eight down-regulated proteins, actin-interacting protein, mitogen activated protein kinase 1, beta actin, annexin A1, glyceraldehyde 3-phosphate dehydrogenase, transforming protein RhoA, acidic leucine-rich nuclear phosphoprotein 32 family member B, and a currently unidentified protein. A subset was validated on both the transcript and protein levels in normal human peripheral blood mononuclear cell cultures treated with valproic acid. These proteins comprise a number of functional classes that may be important to the biology of AD and to the therapeutic action of valproate. These data also suggest the potential of using peripheral leukocytes to monitor pharmaceutical action for neurodegenerative diseases.Neurobiology of aging 06/2007; 29(11):1631-43. DOI:10.1016/j.neurobiolaging.2007.04.004 · 4.85 Impact Factor
Conference Paper: Scaling of compensated MOSFETs towards submicron dimensions[Show abstract] [Hide abstract]
ABSTRACT: The punch-through and turn-on mechanism of a compensated MOSFET are analyzed and compared with measured subthreshold characteristics. On this basis it is argued that the approach for scaling down p-channel MOSFETs in CMOS-VLSI is different from that of n-channel devices. Satisfactory operation of 0.5 µm devices is demonstrated.Electron Devices Meeting, 1984 International; 02/1984
Conference Paper: Dual-band circularly polarized microstrip-fed shorted ring-slot rectenna[Show abstract] [Hide abstract]
ABSTRACT: A dual-band circularly polarized (CP) microstrip-fed shorted ring-slot rectenna (rectifying antenna) was designed and its reception performance from both broadside directions was measured and compared at 2.45 GHz and 5.8 GHz ISM bands. CP performance at the lower frequency band was very similar for both directions of reception whereas considerable deviation was detected at the higher frequency band.Antennas, Propagation and EM Theory, 2003. Proceedings. 2003 6th International SYmposium on; 01/2003